Global regulators set out principles for safe AI across the medicines lifecycle

From discovery to manufacturing and post-marketing surveillance, new joint principles from the European Medicines Agency and US Food and Drug Administration are aimed to ensure that AI in medicines development is human-centred, risk-based and transparent.…
Published: 18 March 2026